TITLE:
Case Report: Feasibility and Safety of Autologous NK Cell Therapy in Patients with Cancer
AUTHORS:
Supansa Nilubol, Worawit Kitisakronnakorn, Pimjai Naigovit
KEYWORDS:
Natural Killer Cells, NK Cell Therapy, Cancer, Mono-Treatment, Rejuvenation
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.12 No.12,
December
27,
2021
ABSTRACT: This study reported two
cases of Thai cancer patients, including a 36-year-old female with thyroid
cancer of more than 5 years and a 64-year-old male with lung and colon cancers
of more than 10 years. The written informed consent was provided for autologous
natural killer (NK) cell infusion at the anti-ageing and regenerative medicines
clinic. Briefly, the blood was taken from the patient for NK cell count and
their cytotoxic activity. Then, the patient’s NK cells were expanded in
vitro, characterized and then counted before being delivered to the same
patient by a single intravenous infusion. The vital signs and general physical
examinations were observed for 2 - 6 hours
after the infusion. The patients were discharged if there were no adverse
effects. The data showed the increasing number of NK cells and level of
cytotoxic activity after the NK cell treatment, compared to the pre-treatment.
In addition, the increasing total live cell concentration, as identified by the
high percentage of CD56dim/CD16bright cytotoxic NK cells,
at day 21 of the NK cell expansion was consistent with the increasing cytotoxic
activity of the patients after the treatment. Here, we demonstrated that this
autologous NK cell therapy might be feasible; however, the study did not aim to
evaluate the anti-cancer effect.